BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.500
+0.120 (8.70%)
Apr 23, 2025, 4:00 PM EDT - Market closed
BeyondSpring Employees
BeyondSpring had 40 employees as of December 31, 2024. The number of employees increased by 4 or 11.11% compared to the previous year.
Employees
40
Change (1Y)
4
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$278,075
Market Cap
60.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
BYSI News
- 27 days ago - BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewsWire
- 3 months ago - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies - GlobeNewsWire
- 3 months ago - SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - GlobeNewsWire
- 5 months ago - BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting - GlobeNewsWire
- 7 months ago - BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus
- 7 months ago - BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - GlobeNewsWire
- 7 months ago - BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - GlobeNewsWire
- 8 months ago - BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - GlobeNewsWire